Why Farbe Firma is the Top Manufacturer of Lincomycin Injection
- Maulik Sudani
- 2 hours ago
- 9 min read
Last Updated: July 4, 2026
TL;DR: Lincomycin Injection - a sterile aqueous solution of lincomycin hydrochloride, the lincosamide antibiotic that binds the bacterial 50S ribosomal subunit and blocks protein synthesis, active against Gram-positive cocci such as staphylococci and streptococci and against many anaerobes, supplied commonly as a 300 mg/mL solution (expressed as lincomycin base) in a glass ampoule or vial for deep intramuscular injection or, after dilution, slow intravenous infusion - is the antibiotic clinicians use for serious staphylococcal, streptococcal and anaerobic infections, particularly in patients who cannot receive a penicillin. Because a potency-critical antibiotic is injected into muscle or infused into a vein, each ampoule must deliver a sterile, correctly potent, clear solution held at the right pH, with the HPLC assay and related substances, solution pH, colour and clarity, any preservative content, particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to potency and safety. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Lincomycin Injection at our Gujarat, India facility and supplies it to hospital, surgical, orthopaedic and infectious-disease services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Lincosamide antibiotic - lincomycin hydrochloride binds the 23S rRNA of the bacterial 50S ribosomal subunit and blocks peptide-bond formation, halting protein synthesis in Gram-positive cocci such as staphylococci, streptococci and pneumococci and in many anaerobes, and Lincomycin Injection (a 300 mg/mL aqueous solution given by deep intramuscular injection or, diluted, by slow intravenous infusion) demands a correctly potent, clear, particulate-free solution in every ampoule.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and ampoule and vial filling with cross-contamination controls, control of the lincomycin assay and related substances by HPLC, solution pH, colour and clarity, preservative content where used, particulate and endotoxin, validated terminal moist-heat sterilisation, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, sterilisation and container-closure data, antimicrobial-preservative-effectiveness data where relevant, forced-degradation data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile antibiotic ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Lincomycin Injection Demands a Premium Manufacturer
Lincomycin Injection holds an established place in hospital and surgical medicine across many markets. It is the antibiotic a clinician turns to for serious infections caused by susceptible Gram-positive organisms and anaerobes - staphylococcal and streptococcal infections of the skin and soft tissue, the respiratory tract, and bone and joint, including osteomyelitis, and serious anaerobic infections - and it is particularly valued in patients who are allergic to penicillins, where a beta-lactam cannot be used. Lincomycin is the parent lincosamide, the naturally occurring antibiotic from Streptomyces lincolnensis from which clindamycin was later derived; it works by binding to the 23S ribosomal RNA of the bacterial 50S subunit and blocking the peptidyl-transferase step of protein synthesis, so the organism can no longer build the proteins it needs to grow. What makes the parenteral form distinctive is that it delivers a dependable tissue concentration - including good penetration into bone - in patients who are too unwell to take or reliably absorb an oral antibiotic, so the prescriber depends on an ampoule whose potency and sterility are beyond doubt.
That clinical reality places real demands on the manufacturer. Lincomycin Injection is presented as a sterile aqueous solution of lincomycin hydrochloride - for example 300 mg of lincomycin base per millilitre, as a 2 mL (600 mg) ampoule or as a larger multiple-dose vial - given by deep intramuscular injection or, after dilution in a compatible infusion fluid, by slow intravenous infusion. The route matters to safety as well as potency: undiluted lincomycin must never be given as a rapid intravenous bolus, because rapid high blood concentrations have caused severe hypotension and cardiopulmonary events, so the label and leaflet must set out the dilution and slow-infusion instructions clearly. As an antibiotic, potency is the defining attribute: the assay must confirm the labelled milligrams of lincomycin base, the related-substance methods must detect lincomycin B and the other related substances, and both are controlled by validated HPLC, because an under-strength antibiotic risks treatment failure and the selection of resistant organisms. The aqueous solution is clear and colourless to slightly yellow, its pH held in a defined acidic window where lincomycin hydrochloride is most stable, and it must be free of visible and sub-visible particulate; where a multiple-dose presentation is offered, a preservative such as benzyl alcohol is included and its content and effectiveness are controlled, with the not-for-neonatal-use caution that benzyl alcohol requires. Because lincomycin hydrochloride tolerates heat, the aqueous solution is generally terminally sterilised by a validated moist-heat cycle, which gives the highest sterility assurance, with endotoxin held low and container-closure integrity assured. Choosing a Lincomycin Injection manufacturer that treats antibiotic assay accuracy, pH and preservative control and validated sterilisation as core disciplines is what protects the patient at the point of care.
What Sets a World-Class Lincomycin Injection Manufacturer Apart
A world-class manufacturer of Lincomycin Injection invests in three areas that weaker suppliers underfund: precise, validated control of the lincomycin assay and related substances by HPLC - confirming the labelled potency in milligrams of base and detecting lincomycin B and the other related substances an antibiotic solution can contain or form; rigorous cross-contamination control, because an antibiotic must be made under segregation and cleaning-validation regimes that prevent trace carryover into or out of other products; and tender-ready dossier support, including the sterilisation, preservative-effectiveness and stability data, for an antibiotic procured through hospital-pharmacy, surgical and ministry-of-health channels. It starts with the raw materials - pharmacopoeial lincomycin hydrochloride of controlled potency and impurity profile, water for injection, pH-adjusting agents and, where used, benzyl alcohol - each sourced from qualified, audited suppliers with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the value of the product is a precise, stable, fully potent dose of a sterile antibiotic, the assay, the related substances and the sterility assurance are treated as central evidence rather than supporting annexes.
Compounding and filling then have to build - and defend - a correctly potent, clear, pH-stable antibiotic solution. The lincomycin hydrochloride is dissolved in water for injection, the pH adjusted into its stable acidic window, any preservative incorporated for multiple-dose presentations, and the solution polished by filtration to remove particulate. The solution is passed through a sterilising-grade filter and filled into glass ampoules or vials under ISO Class 5 conditions, the containers sealed and terminally sterilised by a validated moist-heat cycle locked into the master batch record, giving a robust sterility assurance level for the aqueous solution. Filled units are 100 % inspected for fill, seal, clarity, colour and particulate; in-process and release testing confirm the lincomycin assay and the delivered milligrams of base, the related-substance profile by HPLC, solution pH, colour and clarity against defined limits, the preservative content where used, visible and sub-visible particulate matter, deliverable volume, and that endotoxin is held well within limits so the solution is safe for intramuscular or, after dilution, intravenous use. Because the product is a potency-critical antibiotic, the assay, the related substances and the pH are confirmed before and after the sterilisation cycle, so the solution that leaves the plant is the same fully potent, clear, in-specification solution the specification requires - delivering the full labelled dose with no loss of potency and no out-of-limit degradation in the container across shelf life.
Quality Systems Behind Every Lincomycin Injection
Every Farbe Firma Lincomycin Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of lincomycin against reference standards with confirmation of the delivered milligrams of base, control of related substances including lincomycin B, solution pH, colour and clarity of solution against defined limits, preservative content and antimicrobial effectiveness where a multiple-dose presentation is offered, deliverable volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the glass ampoule or vial. Certificates of analysis are issued with full traceability back to each lincomycin lot, the primary-packaging lot and the qualified person responsible for release. Because the product is a terminally sterilised antibiotic whose clinical value depends on delivered potency, the assay, the related substances and the pH are qualified both before and after the sterilisation cycle so the antibiotic's stability to heat is demonstrated rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated terminal-sterilisation and filling equipment with 100 % inspection, sterilising-grade filtration with filter-integrity testing, dedicated antibiotic handling with cleaning validation and cross-contamination controls, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because an antibiotic given into muscle or the bloodstream must deliver its full labelled potency to clear the infection and to limit the selection of resistant organisms, we treat the assay, the related substances, the pH, the preservative content and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated conditions, with the assay, related substances and preservative content followed across the study, so the solution stays fully potent and within specification across the labelled shelf life, and the storage instructions on the label are supported by real data.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Lincomycin Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad antibiotic, anti-infective and general-injectables portfolio. For Lincomycin Injection specifically, we supply the lincosamide antibiotic as a 300 mg/mL aqueous solution of lincomycin hydrochloride in glass ampoules and vials, together with other strengths and fill volumes, under WHO-GMP conditions, with country-specific strengths, fill volumes, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the assay, related-substance, sterilisation, preservative-effectiveness and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Lincomycin Injection can request the assay, related-substance and accelerated-stability summaries up front, which is often the deciding technical evidence for an antibiotic injectable in hospital-formulary and ministry-of-health review, since it is the confirmed potency of a fully active antibiotic and a validated sterility assurance that separate a dependable lincomycin injection from an unreliable one.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability data, forced-degradation packages, sterilisation, preservative-effectiveness and container-closure reports, translated package inserts and artwork - including the deep-intramuscular administration instruction, the essential dilute-and-infuse-slowly instruction for intravenous use, the not-for-rapid-intravenous-bolus warning, and the storage directions - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Lincomycin Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the antibiotic compounding, filling and sterilisation suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through lincomycin sourcing and impurity control, the design of a clear, pH-stable antibiotic solution, the assay and related-substance strategy by HPLC including the control of lincomycin B, the validation of the terminal moist-heat sterilisation cycle, preservative selection and antimicrobial-effectiveness testing for multiple-dose presentations, cross-contamination and cleaning-validation controls for antibiotic manufacture, colour, clarity and particulate control, fill and potency accuracy, endotoxin control, container-closure integrity and shelf-life choices in real detail. For an antibiotic where assay accuracy, sterility and stability directly govern potency and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Lincomycin Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Lincomycin Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated antibiotic compounding and ampoule and vial filling with cross-contamination controls, sterilising-grade filtration, validated terminal moist-heat sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and presentations of Lincomycin Injection do you supply?
Our lincosamide antibiotic solution is available as a 300 mg/mL aqueous solution of lincomycin hydrochloride (expressed as lincomycin base) in glass ampoules and vials, for deep intramuscular injection or, after dilution, slow intravenous infusion. Custom strengths, fill volumes, single- and multiple-dose formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Lincomycin Injection mainly used for?
Lincomycin Injection is used to treat serious infections caused by susceptible Gram-positive organisms - staphylococci, streptococci and pneumococci - and by many anaerobes, including skin and soft-tissue, respiratory, and bone and joint infections such as osteomyelitis, and it is particularly useful in patients allergic to penicillins. It is given by deep intramuscular injection or, after dilution, by slow intravenous infusion and must not be given as a rapid intravenous bolus. Farbe Firma verifies the assay, related substances, pH, colour and clarity, particulate matter and endotoxin at release so each ampoule delivers a fully potent, sterile solution.
Can Farbe Firma support country-specific registrations for Lincomycin Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability data, related-substance and forced-degradation packages, sterilisation, preservative-effectiveness and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Lincomycin Injection contract manufacturing?
MOQs vary by strength, fill volume, single- or multiple-dose format, label complexity and dossier requirements. For our ampoule and vial presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments